Article Review: Impact of extended 177Lu Lu PSMA 617 therapy on absorbed kidney dose and CKD EPI values how long can therapy be safely continued

Objectives This study evaluated the impact of extended [177Lu] Lu-PSMA-617 therapy on kidney function in patients with metastatic castration-resistant prostate cancer (mCRPC). It assessed the cumulative renal absorbed dose (cRD) and its influence on...